Advertisement

Organisation › Details
Boehringer Ingelheim (Group)
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development.
*
![]() |
Start | 1885-01-01 established |
![]() |
Industry | pharmaceutical |
![]() |
Person | Boehringer, Christian (Boehringer 201207 Chairman of Shareholders’ Committee) |
Person 2 | Barner, Andreas (Boehringer) | |
![]() |
Region | Ingelheim |
Country | Germany | |
Street | 173 Binger Str. | |
City | 55216 Ingelheim | |
Tel | +49-6132-770 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | I: 50,001 to 100,0 (2019-12-31) |
Currency | EUR | |
Annual sales | 18,997,000,000 (sales, net, consolidated (2019) 2019-12-31) | |
Profit | 2,721,000,000 (2019-12-31) | |
Cash | 2,195,000,000 (2019-12-31) | |
* Document for �About Section�: | ||
Record changed: 2021-01-12 |
Advertisement

More documents for Boehringer Ingelheim (Group)
- [1] Boehringer Ingelheim. (1/12/21). "Press Release: Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies". Ingelheim, Oxford & London....
- [2] Boehringer Ingelheim. (1/11/21). "Press Release: Quantum Computing. Boehringer Ingelheim and Google Partner for Pharma R&D". Ingelheim & Mountain View, CA....
- [3] Boehringer Ingelheim. (12/18/20). "Press Release: New SARS-CoV-2 Neutralizing Antibody Enters Clinical Phase". Cologne, Marburg, Braunschweig & Ingelheim....
- [4] Boehringer Ingelheim. (12/10/20). "Press Release: Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates". Ingelheim & Basel....
- [5] Boehringer Ingelheim. (12/9/20). "Press Release: Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program". Ingelheim & Ochsenhausen....
- [6] Boehringer Ingelheim. (12/7/20). "Press Release: Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders – a Novel Approach to Fight Cancer". Ingelheim & Vienna....
- [7] Boehringer Ingelheim. (9/17/20). "Press Release: Boehringer Ingelheim and Mirati Therapeutics Annonce Clinical Collaboration to Study BI 1701963, a SOS1::pan-KRAS Inhibitor in Combination with MRTX849, a KRAS G12C Selective Inhibitor". Ingelheim & San Di...
- [8] Boehringer Ingelheim. (9/11/20). "Press Release: Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia". Ingelheim & New...
- [9] Boehringer Ingelheim. (9/7/20). "Press Release: Boehringer Ingelheim Discontinues Development of BI 1467335 for Diabetic Retinopathy". Ingelheim & Sydney....
- [10] BiomX Inc.. (9/2/20). "Press Release: BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for Inflammatory Bowel Disease". Ness Ziona....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top